GenVec

GenVec

Employees:
20
Market Cap:
$13.59 million
Revenue:
$1 million
5 Year Trend:
50.8%
Net Income:
$-5.79 million

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The companys lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. Wikipedia

Employees:
20
Market Cap:
$13.59 million
Revenue:
$1 million
5 Year Trend:
50.8%
Net Income:
$-5.79 million

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The companys lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. Wikipedia

Feb 20, 7:16 PM

Congratulations to GenVec Chairman Wayne Hockmeyer on his receipt of a Lifetime Achievement Award from the Tech Council of Maryland.

Sep 20, 11:47 AM

GenVec Welcomes Stefan Loren to its Board of Directors Dr. Loren is currently a principal at Westwicke Partners. Prior to joining Westwicke, he worked as an Analyst/Portfolio Manager with Perceptive Advisors, a health care hedge fund, and MTB Investment Advisors, a long-term oriented family of equity funds. His focus areas included biotechnology, specialty pharmaceuticals, life science tools, and health care service companies. Prior to moving to the buy side, Dr. Loren was Managing Director, Health Care Specialist/Desk Analyst for Legg Mason where he discovered, evaluated, and communicated investment opportunities in the health care area to select clients. In addition, he assisted both advising management teams on strategic options. He started his Wall Street career as a sell side analyst at Legg Mason covering biotechnology, specialty pharmaceuticals, life science tools, pharmaceuticals, and chemistry outsourcing companies. While in this position, his "Select List" picks returned an average 118% upside, and his portfolio recommendations beat the Nasdaq Biotechnology and S&P indices in six of six years. In his research career, Dr. Loren was an early member of Abbott Laboratories Advanced Technologies Division, analyzing and integrating new technological advances in Abbott's pharmaceutical research. Before industry, he was a researcher at The Scripps Research Institute, working with Nobel Laureate K. Barry Sharpless on novel synthetic routes to chiral drugs. Dr. Loren received a doctorate in Organic/Pharmaceutical Chemistry from the University of California at Berkeley and an undergraduate degree in Chemistry from UCSC. His scientific work has been featured in Scientific American, Time, Newsweek, and Discover, as well as other periodicals and journals.

Feb 17, 4:21 AM

We like the orange, but we strongly considered blue as well.

Dec 29, 0:22 PM

GenVec CEO, Paul Fischer signing the agreement with Merial. Photographed by Bryan Butman, Ph.D., GenVecs Senior Vice President of Vector Operations.